GE Healthcare Life Sciences to Expand KUBio Through Close Collaboration with Pharmadule Morimatsu

November 21, 2019

GE Healthcare Life Sciences has announced it will be working closely with Pharmadule Morimatsu to expand its KUBio “factory in a box” so that biopharma manufacturers will be able to quickly scale up vaccines, viral vector-based therapies, and other novel modalities.

GE Healthcare Life Sciences has announced it will be working closely with Pharmadule Morimatsu to expand its KUBio “factory in a box” so that biopharma manufacturers will be able to quickly scale up vaccines, viral vector-based therapies, and other novel modalities.

Olivier Loeillot, general manager BioProcess at GE Healthcare Life Science, commented on the partnership in a Nov. 20, 2019 press release. “We are combining our decades-long expertise in biomanufacturing with Pharmadule’s proven excellence in modular construction to support the growth of the biopharmaceutical industry. What biomanufacturers need is fast access to reliable technologies, cost-effective investments, and speed to market,” he said. “KUBio offers all this, while continuing to extend and adapt to the dynamics of the market.”

“Joining expertise with GE Healthcare Life Sciences is an important milestone. Through this collaboration, we will leverage our capacity to execute effective projects from conceptual design to a qualified modular facility and support the expansion of the KUBio biomanufacturing facility offering,” added Helen Zhang, CEO of Pharmadule. “This fits very well with our modular concept, which includes global turn-key delivery, from early design through fabrication and installation up to operational qualification on site.”

Source: GE Healthcare Life Sciences